Can We Slow Aging? Rapamycin with Dr. Matt Kaeberlein

In this episode, Elizabeth Tringali sits down with Dr. Matt Kaeberlein, a leading aging researcher focused on the mechanisms that drive aging, including mTOR signaling and the drug rapamycin.Matt breaks down what mTOR actually is (and why it matters), why longevity medicine requires evidence and comfort with uncertainty, and what we can realistically conclude from animal data vs. human data. You’ll hear a clear, science-first conversation on rapamycin: immune modulation vs. “immune suppression,” common side effects, why weekly dosing is different than transplant dosing, and what early findings suggest for APOE4 carriers, post-viral syndromes like long COVID, and chronic inflammation.They also zoom out to the foundations Matt believes move the needle most: the four pillars he uses at OptiSpan (eat, move, sleep, connect), plus practical guidance on protein, fiber, CGMs, and why fear-based wellness marketing is a problem. Finally, Matt shares an update on the Dog Aging Project’s randomized rapamycin trial—one of the most fascinating real-world studies in the field—and what he expects the next 20 years of longevity medicine to look like.Learn More about Dr. Matt Kaeberlein's research at Optispan.lifeLearn More about the Dog Aging ProjectVisit Tringali Vibrant HealthShop the Tringali Vibrant Health Online Supplement Store